Pablo Nenclares, Consultant Clinical Oncologist at Barts Health NHS Trust and Honorary Associate Professor at UCL, posted on LinkedIn:
“I am thrilled to announce a double global first at Barts Health NHS Trust –
First global site activated for the OrigAMI-5 clinical trial.
First global participant consented and treated.
This achievement showcases what is possible when collaboration, speed and patient focus come together.
A huge shoutout to the outstanding set up team at Barts Cancer Institute (Queen Mary University of London), the Head and Neck Research Team at Barts, the resident doctors in the team (Ladan Alizadeh) and the invaluable partnership and constructive collaboration with Johnson & Johnson.
Together we are accelerating innovation and improving outcomes for patients with head and neck cancer.”
More posts about Barts Cancer Centre .